期刊文献+

利妥昔单抗治疗系统性红斑狼疮出现血栓栓塞并文献复习

Thrombosis Associated with Rituximab Therapy in Lupus Patients:A Rare Adverse Effect
下载PDF
导出
摘要 目的与利妥昔单抗相关血栓的不良反应非常罕见,通过学习1例使用利妥昔单抗后出现严重血栓事件患者的临床特点,进一步了解利妥昔单抗的不良反应。方法详细报道1例系统性红斑狼疮(systemic lupus erythematosus,SLE)合并抗磷脂抗体综合征(anti phospholipid syndrome,APS)患者使用利妥昔单抗后出现血栓的临床表现。结果该患者在使用利妥昔单抗治疗3个月后,PLT正常,狼疮不活动,但出现下肢深静脉血栓和肺栓塞。结论利妥昔单抗治疗SLE有效,但给予SLE合并APS患者使用时要警惕血栓形成的风险。 Objective Thrombosis associated with rituximab is rare. We study the clinic manifestation of the patient who developed severe thrombosis after treated with rituximab in order to learn more about side-effects of rituximab. Methods A patient with systemic lupus erythematosus (SLE)complicated with anti phospholipid syndrome (APS), who was developed severe thrombosis after treated with rituximab, is described in detail. Results A patient was improved after rituximab treatment. But the patient developed deep vein thrombosis and pulmonary embolism three months after rituximab therapy. Conclution Rituximab is effective in SLE, but it has also been associated with some potentially severe adverse effects such as thrombosis.
出处 《中华临床免疫和变态反应杂志》 2013年第2期151-153,I0004,共4页 Chinese Journal of Allergy & Clinical Immunology
基金 国家自然科学基金(30901342)
关键词 利妥昔单抗 血栓 狼疮 rituximab thrombosis lupus
  • 相关文献

参考文献5

  • 1Murray E,Perry M.Off-label use of rituximab in systemic lupus erythematosus:a systematic review[J].Clin Rheumatol,2010,29:707-716.
  • 2Chen H,Zheng W,Su J,et al.Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus-a prospective pilot study[J].Rheumatology (Oxford),2011,50:1640-1644.
  • 3Suzuki K,Nagasawa H,Kameda H,et al.Severe acute thrombotic exacerbation in two cases with anti-phospholipid syndrome after retreatment with rituximab in phase I/II clinical trial for refractory systemic lupus erythematosus[J].Rheumatology,2009,48:198-199.
  • 4Winkler U,Jensen M,Manzke O,et al.Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab,IDECC2B8)[J].Blood,1999,94:2217-2224.
  • 5Koike T,Atsumi T.Antiphospholipid antibodies and cell activation:crucial role of p38MAPK pathway[J].Lupus,2005,24:799-801.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部